Trial Information
Summary: Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-Onset Seizures
A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion
to Lacosamide 400mg/Day Monotherapy in Subjects With Partial-Onset Seizures
The objective of this historical-controlled trial is to assess the efficacy and safety of lacosamide monotherapy in
subjects with partial-onset seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
Inclusion Criteria:
- Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and or complex partial
seizures (with or without secondary generalization)
- Must be experiencing 2 to 40 seizures per 28-day period
- Stable dose of 1 or 2 marketed antiepileptic drugs
- Second AED must be less than or equal to 50% of the minimum effective dose per US product label at
screening
Exclusion Criteria:
- Subject has a history of primary generalized or unclassified seizures
- Seizure disorder primarily characterized by isolated auras
- History of status epilepticus
- Seizures that are uncountable due to clustering
- Has greater than 5 seizures/day
- Subjects taking benzodiazepines, phenobarbital or primidone
- Subject has VNS
- Significant medical or psychiatric condition
- History of alcohol or drug abuse
- History of felbamate, vigabatrin, or ethosuximide use
|
Contact:
UCB Clinical Trial Call Center
Located in:
Northport, AL
Telephone: 1-877-822-9493
|
|

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 6:43:24 AM